Login to Your Account

Year after buyout, Neximmune proceeds with $23M series A

By Marie Powers
News Editor

Tuesday, January 2, 2018

Neximmune Inc. played its cards close to the vest after disclosing its acquisition a year ago by the Barer & Son Capital-led syndicate. The company now is $23 million richer with a series A in hand to develop immunotherapies based on its artificial immune, or AIM, nanotechnology platform.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription